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B cell-specific TIGIT deletion develop spontaneous paralysis with CNS inflammation, but with limited
inflammation in other organs. Our findings suggest that Tim-1+ B cells are essential for maintaining
self-tolerance and restraining tissue inflammation, and that Tim-1 signaling-dependent TIGIT expression
on B cells is essential for maintaining CNS-specific tolerance. A possible critical role of aryl hydrocar-
bon receptor (AhR) in regulating the B cell function is discussed, as we find that AhR is among the
preferentially expressed transcription factors in Tim-1+ B cells and regulates their TIGIT and IL-10
expression.
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SUMMARY
Tim-1, a phosphatidylserine receptor expressed on B cells, induces interleukin 10 (IL-10) production by
sensing apoptotic cells. Here we show that mice with B cell-specific Tim-1 deletion develop tissue inflamma-
tion inmultiple organs includingspontaneousparalysiswith inflammation in thecentral nervoussystem (CNS).
Transcriptomic analysis demonstrates that besides IL-10, Tim-1+ B cells also differentially express a number
of co-inhibitory checkpoint receptors including TIGIT. Mice with B cell-specific TIGIT deletion develop spon-
taneous paralysis with CNS inflammation, but with limited inflammation in other organs. Our findings suggest
that Tim-1+ B cells are essential for maintaining self-tolerance and restraining tissue inflammation, and that
Tim-1 signaling-dependent TIGIT expression on B cells is essential for maintaining CNS-specific tolerance.
A possible critical role of aryl hydrocarbon receptor (AhR) in regulating the B cell function is discussed, as
we find that AhR is among the preferentially expressed transcription factors in Tim-1+ B cells and regulates
their TIGIT and IL-10 expression.
INTRODUCTION
Tim-1 is expressed in immune cells and regulates their responses
in a cell intrinsic manner (Kuchroo et al., 2008; Rennert, 2011).
Tim-1+ B cells can suppress effector T cell responses in experi-
mental models of autoimmunity, allograft rejection, and allergic
airway inflammation (Ding et al., 2011; Xiao et al., 2012, 2015;
Yeung et al., 2015). As a phosphatidylserine receptor, Tim-1
expression on B cells is required for optimal interleukin 10 (IL-
10) production by binding to apoptotic cells (ACs; Xiao et al.,
2015), and IL-10+ B cells are enriched within Tim-1+ cells in both
mice and humans (Ding et al., 2011; Gu et al., 2017; Liu et al.,
2014; Xiao et al., 2012, 2015). Dysregulated IL-10+Tim-1+ B cell
populations have been associated with inflammatory diseases in
humans (Ma et al., 2014; Aravena et al., 2017; Gu et al., 2017; Kris-
tensen et al., 2015; Liu et al., 2014; Mao et al., 2017). Although IL-
10 has been suggested as a primary effector for the regulatory
function of B cells, nevertheless mice with B cell-specific IL-10
deletion do not develop spontaneous inflammation with age (Ma-
dan et al., 2009). We previously reported that Tim-1 mutant mice
developed sporadic spontaneous inflammation in multiple
organs; however, from these studies it was not clear whether
the effect was solely due to loss of Tim-1 function on B cells
and what was the molecular mechanism by which Tim-1+ B cells
mediated their regulatory function. Here we have provided evi-
dence supporting that Tim-1+ B cells, whose function requires
Tim-1 expression and signaling, are critical for maintaining self-
tolerance and limiting tissue inflammation and that this non-redun-
dant regulatory function for Tim-1+ B cells is partly mediated by
expressing the checkpoint receptor TIGIT.
RESULTS
Tim-1BKO Mice Develop Spontaneous Multi-organ
Tissue Inflammation with Age
To firmly evaluate the role of Tim-1 in B cells, we generated Tim-1
floxed (Tim-1fl/fl) mice (Figure 1A) and crossed them
with CD19Cre/Cre mice (Rickert et al., 1997) to produce
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CD19Cre/WTTim-1fl/fl (Tim-1BKO) mice. We confirmed that Tim-1
was effectively deleted only in B cells in Tim-1BKO mice (Fig-
ure 1B); Tim-1BKO B cells stimulated with anti-Tim-1 or ACs
had both reduced basal and induced IL-10 production (Fig-
ure 1C); LPS-activated Tim-1BKO B cells produced less IL-10,
but more proinflammatory cytokines IL-6, IL-23, and IL-12 (Fig-
ure 1D). Consequently, Tim-1BKO B cells as antigen-presenting
cells (APCs) promoted T cell production of the inflammatory cy-
tokines interferon g (IFN-g), IL-17, and granulocyte-macrophage
colony-stimulating factor (GM-CSF), but inhibited IL-10 produc-
tion (Figure 1E). The data support that Tim-1 expression on B
cells determines inflammatory cytokine responses.
Tim-1BKOmice at <6 months of age appeared normal clinically
and histologically, and did not display gross differences in T/B
cells, macrophages, or dendritic cells (Figure S1). Interestingly,
with age Tim-1BKOmice developed multi-organ tissue inflamma-
tion. About 65% of 10+-months-old Tim-1BKO mice showed clin-
ical abnormalities, including weight loss and/or rectal prolapse
(27%), dermatitis (19%), and strikingly, spontaneous experi-
mental autoimmune encephalomyelitis (EAE)-like paralytic dis-
ease (19%; Figure 2A). Histological examination of livers, lungs,
kidneys, intestines, and central nervous system (CNS) showed
that 100% of aged Tim-1BKO mice had immune cell infiltrates in
one or more of these organs: liver (88.5%), lungs (88.5%), kidney
(96.2%), intestines (92.3%), and CNS (26.9%; Figures 2A, 2B,
and S2). Some Tim-1BKO mice with paralysis displayed menin-
geal granulomatous inflammation in the CNS with Touton giant
cells, whose appearance is indicative of hyperactivation of proin-
flammatory myeloid cells (Figure 2B).These data suggest that
with age, loss of Tim-1 expression in B cells leads to a broad
defect in maintenance of tolerance in multiple organs and tis-






Figure 1. Generation of Tim-1BKO Mice
(A) Strategy for generating Tim-1 floxed mice.
(B) Representative fluorescence-activated cell sorting (FACS) plots showing Tim-1 expression in dendritic cells (DCs) and B cells in spleens of 6- to 8-week-old
mice (n = 6–8) ex vivo or in isolated B cells activated with anti-CD40 for two days.
(C) B cells isolated from 6- to 8-week-old mice (n = 5–6 per group) were cultured with anti-Tim-1, apoptotic cells (ACs), or controls. After 60 h, IL-10 production in
culture supernatants was measured by ELISA.
(D) B cells isolated from 6- to 8-week-old mice (n = 5–8 per group) were cultured with lipopolysaccharide (LPS) for 40 h and then examined for their cytokine
production in culture supernatants by BioLegend LEGENDplex.
(E) Foxp3 T cells from 6- to 8-week-old Foxp3-GFP knockin (KI) mice were culturedwith B cells fromWT or Tim-1BKOmice (n = 5 per group) plus soluble anti-CD3
for three days. Then, isolated T cells from the cultures were re-activated with plate-bound anti-CD3, and cytokine production in 40-h cultures was measured by
BioLegend LEGENDplex. *p < 0.01; n.s., not significant. Data are represented as mean ± SEM.
See also Figure S1.








Figure 2. Aged Tim-1BKO Mice Develop Spontaneous Tissue Inflammation
(A) Table and graphs summarize clinical and histological abnormalities in 10- to 18-month-old Tim-1BKO mice.
(B) A Tim-1BKO mouse (#12 in A showed granulomatous inflammation in brain leptomeninges. Boxed area indicates a Touton giant cell shown at higher
magnification. Bar, 100 mm.
(C) Tim-1BKO mice showed enlarged spleens and lymph nodes (LNs). Total splenocyte numbers were determined by trypan blue exclusion.
(D) Representative FACS plots showing phenotypes of immune cells (upper and middle panels) and CD4+ T cell activation (lower panels, gated CD3+CD4+ cells).
(E) Representative FACS plots showing phenotypes of T cell cytokine production (upper and middle panels, gated CD3+ cells) and Foxp3+ Tregs (lower panels,
gated CD3+CD4+ cells).
(legend continued on next page)




Aged Tim-1BKO mice also had lymphadenopathy and spleno-
megaly with a 2- to 8-fold increase in immune cells, predomi-
nantly CD11b+ cells, CD4+ and CD8+ T cells, and B220+ B cells,
compared to control (wild-type [WT], CD19Cre/WT, and CD19Cre/
WTTim-1fl/WT) mice (Figures 2C and 2D). T cells from the Tim-1BKO
mice displayed a more activated/memory-like phenotype
(CD44hiCD62Llow; Figure 2D) with increased IFN-g and IL-17
production, but decreased frequency of Foxp3+ Tregs (Fig-
ure 2E). Aged Tim-1BKOmice also displayed increased activation
of CD11c+ dendritic cells and especially B cells, with increased
expression of major histocompatibility complex (MHC) II and
costimulatory molecules CD80 and CD86 (Figure 2F). Tim-1BKO
mice with rectal prolapse showed predominantly increased
T cells and CD11b+ myeloid cells in colonic lamina propria,
and their CD4+ T cells produced more IFN-g and IL-17 but less
IL-10 (Figure 2G). Thus, B cell expression of Tim-1 is required
for maintenance of tolerance, and loss of Tim-1 expression in
the B cells results in the development of multi-organ inflamma-
tion accompanied by increased activation of and production of
proinflammatory cytokines by T cells, B cells, and myeloid cells.
Tim-1BKO Mice Develop More Severe MOG35–55-Induced
EAE
As aged Tim-1BKO mice developed spontaneous paralysis with
inflammation in the CNS, we asked whether B cell deficiency
of Tim-1 would affect EAE induction in young mice that did not
yet display inflammation. Indeed, following immunization with
MOG35–55, young Tim-1
BKOmice developed more severe clinical
signs of EAE with poorer recovery (Figures 3A and S3A), associ-
ated with increased frequencies of IFN-g+ and IL-17+ T cells, and
reduced frequencies of Foxp3+ Tregs and IL-10+ T cells in the
CNS (Figure 3B), supporting our previous observation that B
cell Tim-1 expression is essential for regulating the balance of
proinflammatory Th1/Th17 cells and regulatory Foxp3+ Tregs
and IL-10+ Tr1 cells (Xiao et al., 2015), and thus the development
of autoimmunity.
Tim-1+ B Cells Highly Express a Set of Negative Immune
Regulators besides IL-10
To gainmore insights into themechanism bywhich Tim-1+B cells
mediate their inhibitory function, we performed RNA sequencing
(RNA-seq) analysis on highly purified Tim-1+ and Tim-1 B cells
from naive WT mice. Of the 15,519 genes detected, 888 were
significantly differentially expressed between Tim-1+ and Tim-1
B cells—768 genes were upregulated in Tim-1+ B cells, while
120 were downregulated (Figure 3C). Interestingly, besides ex-
pressing Tim-1 and IL10, Tim-1+ B cells also express many of
the molecules that have previously been identified as markers
for various IL-10+ Breg cell populations (e.g., CD9, CD25, CD44/
CD138, and CD5/CD1d; Mauri and Menon, 2015; Sun et al.,
2015) or as important for the function of IL-10+ B cells (e.g.,
CD80 and CD86; Mann et al., 2007; Figure 3D). In addition to
IL10, Tim-1+ B cells also highly expressed a panel of other nega-
tive immunemodulators includingEbi3 (a subunit of IL-27),Entpd1
(encoding CD39), Nt5e (encoding CD73), Gitrl, and Fgl2. Interest-
ingly, Tim-1+ B cells also highly expressed a set of checkpoint re-
ceptors including Tigit,CTLA4, Lag3,Pdcd1 (encoding PD-1), and
Havcr2 (encoding Tim-3; Figures 3E and S3B) that have been
associated with CD8+ T cell exhaustion/dysfunction and with
Treg function, and therefore with self-tolerance and regulation of
inflammation and autoimmunity (Anderson et al., 2016; Joller
et al., 2012; Kuchroo et al., 2014).
Tim-1Dmucin is a loss-of-function Tim-1 mutant still expressed
on the cell surface and can be stained with anti-Tim-1 (Xiao
et al., 2012, 2015), thus providing a valuable tool for identifying
Tim-1Dmucin+ cells and for studying the effect of loss of Tim-1
signaling on B cell function. Using B cells from Tim-1Dmucin
mice, we found that loss of Tim-1 signaling (Tim-1Dmucin) did
not alter expression of those genes previously identified as
markers for various IL-10+ B cell subsets (e.g., CD9, CD5/
CD1d, and CD138/CD44) or some genes previously reported
to be involved in B cell regulatory function (e.g., Entpd1, Nt5e,
Gitrl, and Ebi3). Interestingly however, in addition to IL10,
expression of the checkpoint receptors Tigit, Tim-3, Lag3, and
Ctla4, but not Pdcd1, was significantly reduced in Tim-1Dmucin+
cells, of which Tigit expression was most dramatically reduced
(Figure 3F), indicating that their expression requires Tim-1
signaling. As Tim-1+ B cells highly express IL-10 as well as a
panel of negative immune regulators, this suggests that Tim-1+
B cells may maintain self-tolerance and suppress inflammation
by using multiple regulatory mechanisms, e.g., by expressing
checkpoint receptors.
Role of TIGIT in B Cell Function
TIGIT is expressed on natural killer (NK) and T cells and is impor-
tant for regulating immune responses in autoimmunity and can-
cer (Anderson et al., 2016; Joller et al., 2012; 2014). Here we
found that TIGIT was also expressed in B cells and enriched in
Tim-1+ B cells (Figures 3E and 3F). Tim-1 ligation with an anti-
Tim-1 monoclonal antibody (mAb) increased TIGIT expression
and IL-10 production from B cells (Figure 4A), supporting the
idea that Tim-1 signaling in B cells positively regulates TIGIT
and IL-10 expression. Interestingly, we found that AhR is prefer-
entially expressed in Tim-1+ B cells and required for their regula-
tory function. and for Tim-1-mediated expression of TIGIT and
IL-10 by directly binding to their promoters in the B cells (Fig-
ure S4). Although TIGIT and IL-10 are mostly co-expressed,
about 25% to 30% of TIGIT+ B cells are IL-10 and many of
the IL-10+ cells are TIGIT, indicating that expression of TIGIT
and IL-10 can be separable events. Interestingly, while IL-10
blockade with anti-IL-10 mAb did not affect basal or Tim-1 liga-
tion-induced TIGIT expression in B cells (Figure S5A), B cells
from TIGIT-deficient (Tigit/) mice produced less IL-10 upon
treatment with a number of stimuli, indicating that B cells may
(F) Representative FACS plots showing phenotypes of B cells (upper panel, gated CD19+ cells) and DCs (lower panel, gated CD11c+ cells) in LNs from control and
Tim-1BKO mice (n = 5–15).
(G) Representative FACS data showing immune cell phenotypes in colonic LP of Tim-1BKO mice (n = 4). (Left panels) Gated CD45+ cells. (Right panels) Gated
CD45+CD3+CD4+cells. *p < 0.01; n.s., not significant. Data are represented as mean ± SEM.
See also Figure S2.








Figure 3. Young Tim-1BKOMiceDevelopMore Severe EAE, and Tim-1+BCells Differentially Express a Set of Co-inhibitoryMolecules besides
IL10
(A) 6- to 8-week-old mice were immunized with MOG35–55/CFA (Complete Freund’s Adjuvant) and scored daily for clinical EAE signs (n = 10/group). *p < 0.05.
(B) Thirty days after EAE induction, Foxp3 and cytokine expression in CNS-infiltrating CD4+ T cells was determined by flow cytometry.
(C) Heatmap showing differentially expressed genes from RNA-seq analysis of splenic Tim-1 and Tim-1+ B cells from 8-week-old naive WT mice (asymptotic
Student’s t test p% 0.05, absolute fold changeR 2).
(D) Heatmap of selected genes from (C) showing expression of known cell surface molecules associated with IL-10+ B cell subsets in Tim-1+ versus Tim-1 B
cells.
(legend continued on next page)




require TIGIT for optimal IL-10 production (Figure 4B). We then
examined whether Tim-1+ B cells from Tigit/ mice affect EAE
development. As we reported previously, transfer of WT Tim-
1+ B cells significantly inhibited EAE severity (Xiao et al., 2015).
Transfer of Tigit/ Tim-1+ B cells also suppressed disease
severity, but not as effectively as transfer of WT Tim-1+ B cells
(Figure S5B), indicating that TIGIT is required for some of the reg-
ulatory activities of Tim-1+ B cells in suppressing inflammation.
To further understand the role of TIGIT in B cells in vivo, we
generated Tigitfl/fl mice (Figure S5C) and crossed them with
CD19Cre/Cre mice to obtain mice lacking TIGIT specifically in B
cells (CD19Cre/WTTigitfl/fl or TigitBKO). Efficient TIGIT deletion in
B cells was confirmed by flow cytometry (Figure S5D). Up to 5
to 6 months of age, TigitBKO mice displayed a normal phenotype
without any notable defects in Tim-1 expression in B cells or B
cell development (Figures S5E and S5F). When immunized with
MOG35–55, WT, CD19
Cre/WT, and CD19Cre/WTTigitfl/WT showed
comparable EAE development and severity. Compared to these
control mice, young TigitBKO mice developed more severe EAE,
with poorer recovery (Figure 4C), similar to Tim-1BKO mice (Fig-
ure 3A), indicating an important role of TIGIT in B cells in inhibit-
ing CNS inflammation. Unlike Tim-1BKO mice, TigitBKO mice with
age did not show clinical signs of dermatitis, weight loss, or
rectal prolapse (Figure 4D). Interestingly, however, similar to
Tim-1BKO mice, about 20% of TigitBKO mice developed sponta-
neous EAE-like paralytic disease (Figure 4D and Video S1). His-
tological examination of liver, lungs, kidneys, intestines, and
CNS in aged TigitBKO mice revealed that 50% of the mice had
lymphoid infiltrates in various organs/tissues, in contrast to
100% observed in Tim-1BKO mice (Figure 4D). Aged TigitBKO
mice also had fewer and smaller foci of mononuclear cell infil-
trates in livers, lungs, kidneys, and colons than Tim-1BKO mice
(Figure 4E).
Additionally, the incidence of histopathological tissue inflamma-
tion in liver (33.3%versus 88.5%), lungs (33.3%versus 88.5%), in-
testines (44.4% versus 92.3%), and kidneys (5.6% versus 96.2%)
of aged TigitBKOmice wasmuch lower than that in aged Tim-1BKO
mice (Figures 4D, 2A, and S5G), and inflammation was less wide-
spread, as aged TigitBKO mice only had lymphoid infiltrates in two
(22.2%) or three (22.2%) organs/tissues (Figure 4D), whereas
80.7% of aged Tim-1BKO mice had lymphoid infiltrates in four or
five organs/tissues (Figure 2A). As aged TigitBKO and Tim-1BKO
mice had a comparable incidence of spontaneous paralysis, we
examined the brain infiltrates in the mice with paralysis and found
that both strains with paralysis showed about a 4-fold increase of
immune cell infiltrates brains, with increased T cells and especially
CD11b+ myeloid cells, and a decreased frequency of Foxp3+
Tregs (Figure 4F). Young TigitBKO mice, like young Tim-1BKO
mice, showed no defect in Treg frequency, surface CTLA-4,
CD39, and CD73 expression, or suppressive capacity, compared
to control (Figures S5H–S5J).
Examination of peripheral immune compartments in aged Ti-
gitBKO mice demonstrated that those mice without organ/tissue
inflammation had no obvious changes in immune cell infiltrates,
compared to control mice. In contrast, T cells from spleens of
aged TigitBKO mice with CNS infiltrates and paralysis were
more activated and produced more IFN-g and IL-17. Also, levels
of CD11b+ myeloid cells were increased, but there was no
change in the frequency of Foxp3+ Tregs (Figure S5K).
Collectively, these data support that TIGIT, a checkpoint re-
ceptor differentially expressed on Tim-1+ B cells and induced
by Tim-1 signaling, is not only critical for B cell-mediated sup-
pression of inflammation, it is also required for B cell-mediated
induction of tolerance, especially in the CNS.
DISCUSSION
Tim-1 is broadly expressed on multiple cell types and regulates
multiple biological functions (Bonventre, 2014; Kuchroo et al.,
2008; Rennert, 2011; Xiao et al., 2011). Here we have shown
that over 80% of Tim-1BKO mice developed spontaneous multi-
organ tissue inflammation as they age, clearly demonstrating
that Tim-1 expression on B cells is required for maintaining
self-tolerance. Surprisingly, 27% of the Tim-1BKO mice devel-
oped a spontaneous paralysis, indicating that the selective
loss of Tim-1 on B cells is unique in protecting mice from the
development of CNS inflammation, even without immunization
with a CNS antigen or expression of a CNS antigen-specific
TCR or BCR. This emphasizes that in addition to their critical reg-
ulatory role in maintaining self-tolerance systemically, Tim-1+ B
cells have a unique role in maintaining tolerance in the CNS.
Although also targeting CD20 expressing CD8+ T cells (Saba-
tino et al., 2019), the efficacy of anti-CD20 therapy in multiple
sclerosis has been mainly attributed to deletion of proinflamma-
tory B cells and induction of ‘‘regulatory’’ B cells, as the immune
system resets itself to replenish B cells in the repertoire (Li et al.,
2016). Tim-1 is expressed in10% of B cells, yet Tim-1BKOmice
developed both spontaneous and more severe induced CNS
inflammation, supporting that Tim-1+ B cells may be critical in
this context and that Tim-1 signaling is essential for regulating
the balance between ‘‘regulatory’’ and proinflammatory B cells
in order to maintain self-tolerance in tissues including the CNS.
Besides IL-10, Tim-1+ B cells also differentially express a
panel of negative immune regulators, including a set of check-
point receptors that likely contribute to the regulatory function
of Tim-1+ B cells. In support of this, TIGITBKO mice, with age,
preferentially develop spontaneous paralytic disease with CNS
inflammation. It should be emphasized that development of
spontaneous paralytic disease with CNS inflammation has not
been observed previously in mice with global loss of negative
regulatory molecules, including IL-10, CTLA-4, TIGIT, PD-1, or
Tim-3. The checkpoint receptors not only induce CD8+ T cell
exhaustion, but also enhance the regulatory function of Foxp3+
Tregs. Aswe have observed a similar set of checkpoint receptors
expressed on Tim-1+ B cells that regulate tissue inflammation,
this raises an interesting question of whether checkpoint
(E) Heatmap of selected genes from (C) showing expression of well-known negative immune regulators in Tim-1+ versus Tim-1 B cells.
(F) qPCR data of selected genes in WT Tim-1 and Tim-1+B cells and Tim-1Dmucin and Tim-1Dmucin+ B cells, normalized to expression in WT Tim-1 B cells. *p <
0.01 (Tim-1+ versus Tim-1Dmucin+ cells; n = 4). Data are represented as mean ± SEM.
See also Figure S3.
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blockade-induced anti-tumor immunity may also alter the regu-
latory function of B cells that express these checkpoint
receptors.
Our data suggest that Tim-1+ B cells must limit inflammation
through diverse regulatory mechanisms, and we speculate that
individual regulatory mechanismsmay be operational in a partic-
ular tissue and inflammatory setting. TIGIT appears to be prefer-
entially required for Tim-1+ B cell-mediated self-tolerance in the
CNS, and by analogy, there must be other regulatory mecha-
nisms (preferentially or coordinately) responsible for Tim-1+ B
cell-mediated self-tolerance in other organs and tissues. Alter-
natively, loss of individual effector mechanism in Tim-1+ B cells
may only have a limited effect on the regulation of tissue inflam-
mation, but multiple mechanisms may be coordinately working
together in the B cells to regulate tissue inflammation in multiple
organs or multiple tissue specificities.
A recent study has identified AhR as a critical transcription fac-
tor (TF) for the regulatory function of IL-10+Bcells by directly regu-
lating IL-10 and suppressing proinflammatory gene expression
(Piper et al., 2019). We also found that AhR is preferentially ex-
pressed and ranks at the top among TFs expressed in Tim-1+ B
cells (Figure S4A). Maintenance and induction of AhR in these B
cells require Tim-1 expression and signaling (Figure S4B). AhR
is required for Tim-1-mediated expression of IL-10 and TIGIT by
directly binding to their promoters in the B cells (Figures S4C–
S4E). Importantly, AhR is required for the regulatory function of
Tim-1+ B cells in ameliorating EAE severity (Figure S4F). It is
possible that AhR in Tim-1+ B cells also regulates other regulatory
mechanisms, besides IL-10 and TIGIT. In this regard, our compu-
tational analysis has identified putative AhR-binding sites in the
promoter regions of other coinhibitory molecules such as Tim-3
and LAG3. Thus, it is very likely that AhR may serve as a critical
TF responsible for the regulatory activity of Tim-1+ B cells by
directly regulating the module of negative regulators and sup-
pressing proinflammatory factors by binding to their promoters
in these cells. In addition to AhR, our RNA-seq analysis has also
identified a set of other TFs preferentially expressed in Tim-1+ B
cells; however, whether any of these TFs is also required for
Tim-1+ B cell regulatory function, needs further investigation.
In summary, we demonstrate that Tim-1+ B cells are essential
in maintaining self-tolerance and restraining tissue inflammation,
and that the Tim-1/TIGIT axis is required for their optimal regula-
tory function, especially for maintaining tolerance in the CNS.
The regulatory function of Tim-1+ B cells has also been identified
in infections and transplantation (Ding et al., 2011; Liu et al.,
2014; Mao et al., 2017). Thus, further understanding Tim-1+ B
cells and their regulatory mechanisms would be valuable for
treating immune-related diseases by selectively enhancing or in-
hibiting the B cell activity and/or their regulatory mechanisms.
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Figure 4. Immunoregulatory Role of TIGIT in B Cells
(A) Representative FACS plots showing Tim-1, TIGIT, and IL-10-GFP expression in splenic CD19+ B cells from 8-week-old IL10GFP tiger mice (n = 6) after cells
were treated with anti-Tim-1 or control rIgG1 for three days.
(B) Splenic B cells from 8-week-old WT and Tigit/ mice were treated with indicated stimuli for three days and IL-10 production in culture supernatants was
measured by ELISA. *p < 0.01.
(C) 8-week-old mice were immunized with MOG35–55/CFA and scored daily for clinical EAE signs (n = 10 per group; *p < 0.05).
(D) Table and graph summarizing clinical and histological abnormalities in TigitBKO mice.
(E) Representative histological examination of indicated organs/tissues in TigitBKO and Tim-1BKO mice. Tim-1BKO mice showed marked lymphoid infiltrates in
periportal areas of the liver, peribronchial areas, renal cortex, lamina propria, and submucosal areas of the large intestine. The extent of infiltration was much less
in tissues of TigitBKO mice. No tissue inflammation was present in WT mice. Bar in the liver panel, 50 mm, applies to liver and kidney tissue panels; bar in the lung
panels, 100 mm, applies to the lung tissue panels; bar in the intestine panel, 100 mm, applies to the intestine tissue panels.
(F) Phenotypes of brain-infiltrating immune cells determined by flow cytometry in WT (n = 9), TigitBKO (n = 4), and Tim-1BKO (n = 5) mice with spontaneous EAE-like
paralysis. *p < 0.01; n.s., not significant. Data are represented as mean ± SEM.
See also Figures S4 and S5.
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Antibodies
Anti-mouse CD19, Clone 6D5 Biolegend Cat# 115555; RRID: AB_2565970
Anti-mouse B220, Clone RA3-6B Biolegend Cat# 103223; RRID: AB_313006
Anti-mouse CD11b, Clone M1/70 Biolegend Cat# 101257; RRID: AB_2565431
Anti-mouse CD3ε, Clone 145-2C11 Biolegend Cat# 100320; RRID: AB_312685
Anti-mouse TCRb, Clone H57-597 Biolegend Cat# 109230; RRID: AB_2562562
Anti-mouse CD4, Clone RM4-5 Biolegend Cat# 100543; RRID: AB_10898318
Anti-mouse CD8a, Clone 53-6.7 Biolegend Cat# 100744; RRID: AB_2562609
Anti-mouse IFN-g, Clone XMG1.2 Biolegend Cat# 505813; RRID: AB_493312
Anti-mouse IL-17A, Clone TC11-18H10.1 Biolegend Cat# 506904; RRID: AB_315464
Anti-mouse IL10, Clone JES5-16E3 Biolegend Cat# 505008; RRID: AB_315362
Anti-mouse TIGIT, Clone 1G9 Biolegend Cat# 142107; RRID: AB_2565648
Anti-mouse CD62L, Clone MEL-14 Biolegend Cat:#104406; RRID: AB_313039
Anti-mouse/human CD44, Clone IM7 Biolegend Cat# 103012; RRID: AB_312963
Anti-mouse CD11c, Clone N418 Biolegend Cat# 117334; RRID: AB_2562415
Anti-mouse TIM-1, Clone RMT1-4 Biolegend Cat# 119506; RRID: AB_2232887
Anti-mouse CD45 Biolegend Cat# 103108; RRID: AB_312973
Anti-mouse CD138, Clone 281-2 Biolegend Cat# 142506; RRID: AB_10962911
Anti-mouse CD21, Clone CR2/CR1 Biolegend Cat# 123412; RRID: AB_2085160
Anti-mouse CD23, Clone B3B4 Biolegend Cat# 101606; RRID: AB_312831
Anti-mouse PD-1, Clone RMP1-30 Biolegend Cat:#109110; RRID: AB_572017
Anti-mouse LAG-3, Clone C9B7W Biolegend Cat# 125212; RRID: AB_2561517
Anti-mouse Tim-3, Clone 5D12 Biolegend Custom made
Anti-mouse TIM-1, Clone 5F12 Xiao et al., 2015 N/A
Anti-mouse CD93, Clone AA4.1 eBioscience Cat# 17-5892-82; RRID: AB_469466
Anti-mouse FAS, Clone Jo2 BD Biosciences Cat# 557653; RRID: AB_396768
Anti-mouse GL-7, Clone GL-7 BD Biosciences Cat# 562080; RRID: AB_10894953
AffiniPure Fab Fragment Goat Anti-Mouse IgM, m chain
specific
Jackson ImmunoResearch Cat# 115-007-020; RRID: AB_2338477
Anti-mouse AhR, Clone 4MEJJ Thermo Fisher Scientific Cat# 12-5925-82; RRID: AB_2572644
Anti-mouse FoxP3, Clone FJK-16 ThermoFisher Scientific Cat# 17-5773-82; RRID: AB_469457
Chemicals, Peptides, and Recombinant Proteins
Lipopolysaccharide (LPS) Sigma Aldrich Cat# L4391
Dexamethasone Sigma Aldrich Cat# D4902
Phorbol-12-myristate-13 acetate (PMA) Sigma Aldrich Cat# P8139
Ionomycin Sigma Aldrich Cat# I0634
Complete Freund’s adjuvant (CFA) BD Difco Cat# 263810
M. tuberculosis H37 Ra, desiccated BD Difco Cat# 231141
7AAD BD Biosciences Cat# 559925
Golgi Stop BD Biosciences Cat# 554724
Fixable Viability w eFluor 506 Invitrogen Cat# 65-0866-14
MOG35-55 peptide Quality Controlled Biochemicals N/A
Pertussis toxin List Biological Laboratories Cat# 180
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Critical Commercial Assays
LegendPlex (Mouse Th Cytokine Panel) Biolegend Cat# 740005
BD Cytofix/Cytoperm BD Biosciences Cat# 51-2090KZ
BD Perm/Wash BD Biosciences Cat# 51-2091KZ
CellTrace Violet Cell Proliferation Kit Invitrogen Cat# C34557
Fixation/Permeabilization Concentrate Invitrogen Cat# 00-5123-43
Fixation/Perm Diluent Invitrogen Cat# 00-5223-56
Permeabilization Buffer Invitrogen Cat# 00-8333-56
RNeasy Plus Mini Kit QIAGEN Cat# 74134
RNase-Free DNase Set QIAGEN Cat# 79254
iScript cDNA Synthesis Kit Bio-Rad Cat# 1708891
CD19 MicroBeads, mouse Miltenyi Biotec Cat# 130-052-201
SuperScript IV VILO Master Mix Thermo Fisher Scientific Cat# 11756050
TaqMan Fast Advanced Master Mix Thermo Fisher Scientific Cat# 4444557
PicoPure RNA Isolation Kit Thermo Fisher Scientific Cat# KIT0204
Deposited Data
Raw and analyzed data This paper GEO: GSE150786
Experimental Models: Organisms/Strains
Tim-1fl/fl mice This paper N/A
Tigitfl/fl mice This paper N/A
Tim-1BKO mice This paper N/A
TigitBKO mice This paper N/A
Tim-1/ mice Xiao et al., 2015 N/A
Tim-1Dmucin mice Xiao et al., 2015 N/A
Tigit/ mice Joller et al., 2014 N/A
C57BL/6 mice Jackson laboratory Cat# JAX:000664; RRID: IMSR_JAX:000664
CD19Cre mice The Jackson Laboratory Cat# JAX:006785; RRID: IMSR_JAX:006785
Rag1/ mice The Jackson Laboratory Cat# JAX:002216; RRID: IMSR_JAX:002216
B6.129P2-Igh-Jtm1Cgn/J mice The Jackson Laboratory Cat# 002438; RRID: IMSR_JAX:002438
IL10GFP tiger mice The Jackson Laboratory Cat# JAX:008379; RRID: IMSR_JAX:008379
AhRd mice The Jackson Laboratory Cat# JAX:002921; RRID: IMSR_JAX:002921
Software and Algorithms
FlowJo v10.5.0 FlowJo https://ww.flowjo.com
Prism v7.0a and v8.1.2 GraphPad https://ww.graphpad.com
R N/A https://www.r-project.org/
Other
anti-CD3/anti-CD28 beads Invitrogen Cat# 11456D
DNase I Sigma-Aldrich DN25
Collagenase D Sigma-Aldrich Cat# 11088882001




Data and Code Availability
The accession number for the RNA-seq data reported in this paper is GEO: GSE150786
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Tim-1 and Tigit floxed mice were generate on the C57BL/6 background. Targeting vectors containing genomic fragments of the Tim-
1 or Tigit gene were constructed by using C57BL/6 BAC clones. Linearized targeting vector was transfected into B6 embryonic stem
(ES) cells. Homologous recombinants were identified by Southern-blot analysis, and were implanted into foster B6-albino mothers.
Chimeric mice were bred to C57BL/6 mice, and the F1 generation was screened for germline transmission. The Neo gene was
removed by breeding F1 mice with a strain of actin promoter-driven Flipase transgenic mice (Jackson Laboratory, 003800).
C57BL/6 mice (000664), CD19Cre (006785), IL10GFP tiger (008379), AhRd (002921), muMT (002288), and Rag1/ (002216) mice
were purchased from the Jackson Laboratory. Tim-1/, Tim-1Dmucin, and Tigit/ mice, all on the C57BL/6 background, were
described previously (Joller et al., 2014; Xiao et al., 2015). Both females and males were used in the study. Ages of mice were indi-
cated in figure legends. Mice were maintained and all animal experiments were done according to the animal protocol guidelines of
Harvard Medical School.
METHOD DETAILS
Cell purification and cultures
For AC preparation, thymocytes from C57BL/6 mice were treated with 1 mM dexamethasone (Sigma-Aldrich) for 8h. After an exten-
sive wash, ACwere used in cell cultures. Annexin V and propidium iodide (BD Biosciences) staining was used to confirm apoptosis of
thymocytes.
Splenic B cells were purified using MACS columns following staining with anti-mouse CD19 MACS beads. Cells were cultured in
round-bottom 96-well plates in the presence of anti-Tim-1 (clone 5F12), AC, (Fab’)2 fragment anti-IgM, Anti-CD40, IL-21, or their
combinations. After 3 days, IL-10 production in culture supernatants was measured by cytokine bead array (CBA) or ELISA.
MACS purified CD19+ B cells were labeled with PE-anti-Tim-1 (RMT1-4) and then separated into Tim-1+ and Tim-1- B cells by fluo-
rescence-activated cell sorting for further uses.
CD4+CD62LhiCD25 naive CD4+ T cells were purified by fluorescence-activated cell sorting after a MACS bead isolation of CD4+
cells as previously described (Xiao et al., 2015). Naive CD4+ cells were activated with isolated CD19+ B cells plus soluble anti-CD3
(1 mg/ml). After 96 h, cells were collected for further experiments.
Single-cell suspensions from colon lamina propria tissue were prepared using the Lamina Propria Dissociation Kit (Miltenyi Biotec).
Isolated cells were resuspended in culture medium for further analysis. For isolation of CNS-infiltrating mononuclear cells, mice were
first perfused through the left cardiac ventricle with cold PBS. The forebrain and cerebellum were dissected and spinal cords flushed
out with PBS by hydrostatic pressure. CNS tissue was cut into pieces and digested with collagenase D (2.5 mg/ml, Roche Diagnos-
tics) and DNase I (1 mg/ml, Sigma) at 37C for 30 min. Mononuclear cells were isolated by passing the tissue through a 70 mm cell
strainer, followed by a 70%/37% percoll gradient centrifugation. Mononuclear cells were removed from the interphase, washed, and
resuspended in culture medium for further analysis.
For in vitro suppression assay, 5 3 104 FACS-sorted CD3e+ CD4+ CD25- conventional T cells (Tconv) from LNs and spleens of
CD19Cre/WT mice were labeled with 5 mM CellTrace Violet and stimulated with anti-CD3/anti-CD28 beads(Dynabeads, Invitrogen)
in presence of FACS sorted CD3e+ CD4+ CD25+ Treg cells from CD19Cre/WT, TIM-1BKO or TIGITBKO mice. Tconv proliferation was
read out after 72h by flow cytometry and the division index of responder cells was analyzed using FlowJo based on the division
of Cell Trace Violet. Suppression was then calculated with the formula%Suppression = (1-DivTreg/DivAlone) x100% (DivTreg stands
for the division index of responder cells with Tregs, and DivAlone stands for the division index of responder cells activated without
Tregs).
Flow cytometry
For intracellular cytokine staining, cells were stimulated in culture medium containing phorbol 12-myristate 13-acetate (30 ng/ml,
Sigma-Aldrich), ionomycin (500 ng/ml, Sigma-Aldrich), and GolgiStop (1 ml/ml, BD Biosciences) in a cell incubator with 10% CO2
at 37C for 4 h. After surface markers were stained, cells were fixed and permeabilized with Cytofix/Cytoperm and Perm/Wash buffer
(BD Biosciences) according to the manufacturer’s instructions. Then, cells were stained with fluorescence-conjugated cytokine an-
tibodies at RT for 30min before analysis. 7-AAD (BDBiosciences) was also included to gate out the dead cells. All data were collected
on a FACSCalibur or an LSR II (BD Biosciences) and analyzed with FlowJo software (TreeStar).
EAE
Mice were immunized subcutaneously in the flanks with an emulsion containing MOG35–55 (80 mg/mouse) andM. tuberculosisH37Ra
extract (3 mg/ml, Difco Laboratories) in CFA (100 ml/mouse). Pertussis toxin (100 ng/mouse, List Biological Laboratories) was admin-
istered intraperitoneally on days 0 and 2. Mice were monitored and assigned grades for clinical signs of EAE as previously described




(Xiao et al., 2015). To evaluate the suppressive ability of Tim-1+B cells, purified total B cells or Tim-1+B cells were transferred i.v. into
WT recipients. Hosts were then immunized to induce EAE.
Chromatin immunoprecipitation (ChIP)
B cells from WT and AhRd mice were treated for 24 h with anti-Tim-1 or control rIgG1, fixed with 1% formaldehyde for 15 min, and
quenched with 0.125 M glycine. Chromatin was isolated and sheared to an average length of 300–500 bp by sonication. Genomic
DNA (Input) was prepared by treating aliquots of chromatin with RNase, proteinase K and heated for de-crosslinking, followed by
ethanol precipitation. AhR-bound DNA sequences were immuno-precipitated with an AhR-specific antibody (Biomol SA-210).
Crosslinks were reversed by incubation overnight at 65 C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol
precipitation. Quantitative PCR (qPCR) reactions were carried out in triplicate and experimental Ct values were converted to copy
numbers detected by comparison with a DNA standard curve run on the same PCR plates. Copy number values were normalized
for primer efficiency using the values obtained with input DNA and the same primer pairs.
RNA isolation, real-time PCR, and histology
RNAwas extracted with RNeasy Plus kits (QIAGEN) and cDNAwasmade using iScript (BioRad). All of the real-time PCR probes were
purchased from Applied Biosystems. Quantitative PCRs were performed using ViiA 7 Real-Time PCR System (Applied Biosystems).
Tissues and organs from mice were fixed in 10% neutral buffered formalin for > 12 h, processed, embedded in paraffin wax,
sectioned, and stained with H&E using standard procedures. Evaluations were made in a blinded fashion.
RNA-seq assay
Samples from isolated Tim-1- and Tim-1+B cells were processed with the SMART-Seq2 protocol (Picelli et al., 2013), and sequenced
on Illumina Hi-Seq 2500. The paired-end 38bp reads sequenced (26.53M ± 1.62M pairs of reads per sample) for each of the 8 sam-
ples (4 Tim-1+ and 4 Tim-1- B cell samples derived from naive WT mice) were aligned to the mouse mm10 UCSC reference genome
using Tophat version 2.0.10 (Kim et al., 2013) with default settings (read alignment rate of 82.81% ± 0.44%properly mapped pairs per
sample). Gene expression levels were quantified for 22,815 genes in themousemm10 UCSC reference gene annotations using Cuff-
quant in the Cufflinks suite version 2.2.1 (Trapnell et al., 2012). These levels were subsequently normalized across all 8 samples using
Cuffnormwith default settings based on ‘‘geometric’’ normalization, which normalizes samples based on themedian expression level
in each sample, thus reporting normalized expression levels (FPKM: fragments per kilo bases of exons for per million mapped reads).
Out of the 22,815 quantified reference genes, 15,519 genes were detected in at least one of the 8 samples at a normalized FPKM level
> 0. Differential gene expression analysis comparing the 4 Tim-1+ and 4 Tim-1- B cell samples was performed by estimating the
asymptotic t test (Student’s t-distribution) p values, False Discovery Rate (FDR) (Benjamini and Hochberg) values and fold-changes
using the ComparativeMarkerSelection module in GenePattern (Reich et al., 2006). Significantly differentially expressed genes were
identified using the asymptotic t test p value % 0.05 and absolute fold change R 2 selection criteria. Heatmaps visualizing the
normalized gene expression levels (zero mean centering and unit standard deviation scaling of the expression levels for each
gene, followed by saturating these normalized gene expression levels at +1 and 1) were generated using GENE-E/Morpheus.
QUANTIFICATION AND STATISTICAL ANALYSIS
The clinical score and incidence of EAE were analyzed by Fisher’s exact test (Figures 3A, 4C, S4F, and S5B), and comparisons for
results (mean ± SEM) of BioLegend LEGENDplex (Figures 1D and 1E), ELISA (Figures 1C, 4B, and S4C), FACS (Figures 2C, 2E, 3B,
4F, S1C–S1F, S4D, S5D–S5F, and S5H–S5J), and real-time PCR (Figures 3F, S4B, and S4E) were analyzed by Student’s t test.
p < 0.05 was considered significant. Significantly differentially expressed genes for RNA-seq analysis were identified using the
asymptotic t test p value% 0.05 (Figures 3C–3E and S4A).
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